Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580202 | 1.00 | MAPT (0.68) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL2563862 | 0.85 | MAPT (0.52) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL2563864 | 0.85 | MAPT (0.52) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL3719083 | 0.82 | MAPT (0.67) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL2563570 | 0.81 | MAPT (0.66) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL2566747 | 0.79 | KMT2A (0.62) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL2566334 | 0.78 | S1PR1 (0.51) | SIRT1MAPKAPK2 | |
| SCHEMBL2566332 | 0.78 | S1PR1 (0.51) | SIRT1MAPKAPK2 | |
| SCHEMBL4725046 | 0.75 | MEN1 (1.00) | MAPTGAAHTTNPSR1MEN1 | |
| SCHEMBL16266024 | 0.75 | MAPT (0.77) | MAPTGAAHTTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222668-B1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2222668-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009078983-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | MAPT 3431/4885GAA 4561/4885HTT 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.